Endomimetics™ Awarded $300 Thousand Phase I SBIR Grant to Automate and Evaluate a Novel 3D In Vitro Model for Use in Atherosclerosis Drug Discovery and Development
Endomimetics™ Awarded $2.8 Million Phase II SBIR Grant to Develop and Evaluate the Potential of Bionanomatrix™ to Improve Performance and Patient Outcomes in the Treatment of Brain Aneurysms
Endomimetics™ Awarded $292 Thousand, One-Year NIH/SBIR Grant to Develop and Evaluate Potential of Bionanomatrix™ to Reduce Infectious and Inflammatory Complications of Knee Arthroplasty
Endomimetics™ Awarded $292 Thousand, One-Year NIH/SBIR Grant to Develop and Evaluate Potential of Bionanomatrix™ to Reduce Infectious and Inflammatory Complications of Knee Arthroplasty
Endomimetics™ Announces a Research Collaboration Agreement with BISCO, Inc., to Support Development of a Dental Application of Bionanomatrix™
At Endomimetics, we are committed to improving outcomes for patients undergoing surgical procedures and device implantation. To support us in the mission, we are continually seeking collaborations and strategic partnerships with leading medical device companies worldwide to advance our early- and clinical-stage programs.
Reid Millican, MS
Director, Business Development
Reid Millican, MS
Director, Business Development
Chief Executive Officer
[email protected]